<DOC>
	<DOCNO>NCT01781104</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability well effect RM-131 colonic transit , bowel consistency , bowel habit , abdominal pain , abdominal symptom patient chronic constipation .</brief_summary>
	<brief_title>Phase 2 Study Evaluate Safety Efficacy RM-131 Administered Patients With Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Inclusion criterion Able provide write informed consent prior study procedure , willing able comply study procedure . Diagnosis chronic IDIOPATHIC constipation , include experience constipation 12 week precede 12 month ( define Rome III criterion Functional Constipation , patient must meet modified criterion history â‰¤4 average defecation per week ) Stable concomitant medication ( change regimen least 2 week prior baseline period ) Body mass index 1840 kg/m2 Females must lactate pregnant Exclusion criterion Unable/unwilling provide inform consent comply study procedure Diagnosis secondary constipation e.g . underlie general neurological disease Parkinsonism , multiple sclerosis , disease associate peripheral neuropathy , iatrogenic constipation Structural metabolic disease affect GI system NOTE : Patients clinical suspicion upper low GI obstruction must evaluate per standard care obstruction rule screen Unable withdraw follow medication 48 hour prior baseline period throughout study ( except protocol define rescue medication ) : Medications alter GI transit include laxative , magnesium aluminum contain antacid , prokinetics , erythromycin , narcotic , anticholinergic , tricyclic antidepressant , SNRI new antidepressant Selective serotonin reuptake inhibitor ( SSRI ) antidepressants permissible low , stable dos Analgesic drug include opiate , NSAIDs COX2 inhibitor GABAnergic agent Benzodiazepines NOTE : stable dos thyroid replacement , estrogen replacement , low dose aspirin cardioprotection , birth control ( adequate backup contraception druginteractions birth control conduct ) permissible Drugs low therapeutic index , warfarin , digoxin , antiseizure medication History surgery within 60 day screen Acute chronic illness history illness , opinion Investigator , could pose threat/harm patient obscure interpretation laboratory test result interpretation study data frequent angina , Class III IV congestive heart failure , moderate impairment renal hepatic function , poorly control diabetes , etc History hypersensitivity mannitol ( ingredient active placebo study medication ) Clinically significant abnormality screen laboratory physical examination determine Investigator Abnormal 12lead electrocardiogram ( ECG ) , include evidence acute myocardial subendocardial ischemia clinically significant arrhythmias conduction abnormality ( include prolong QTc &gt; 500 msec ) abnormal blood pressure screen except minor deviation deem clinical significance Investigator Acute GI illness within 48 hour initiation baseline period ALT AST &gt; 1.2 X upper limit normal screen Females pregnant breastfeed History excessive alcohol use substance abuse Participation investigational clinical study within 30 day prior dose present study Any reason , opinion Investigator , would confound proper interpretation study Exclusion criterion end baseline period In addition , patient randomize doubleblind treatment comparison baseline period : use rescue medication laxatives , beyond allow protocol demonstrate lack compliance average 4 spontaneous bowel movement per week Substudy patient : demonstrate slow colonic transit end baseline period ( GC 24 &gt; 2.4 ) Women childbearing potential : positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>constipation gastric empty gastrointestinal motility ghrelin</keyword>
</DOC>